The Indication for Common Toxicity Criteria (CTC) Grading of Peripheral Neuropathy Questionnaire (ICPNQ) is a valid instrument to distinguish the highest chemotherapy-induced peripheral neuropathy (CIPN) CTC grades from the lower CTC grades required to inform dose modification of chemotherapy decisions in clinical practice, a new study published online ahead of print in the journal Supportive Care in Cancer has shown.1
CIPN can negatively impact the health-related quality of life of patients with multiple myeloma, with dose modification being the only way to minimize the effect. Therefore, researchers developed the ICPNQ in order to measure CIPN in clinical practice, which can be completed in 5 minutes by patients.
For the study, researchers enrolled 156 patients with multiple myeloma diagnosed between 2000 and 2014. Patients completed the ICPNQ, as well as the EORTC QLQ-CIPN20 and the EORTC QLQ-C30.
Results showed that 65% of patients reported grade 2 to 3 neuropathy per the ICPNQ. According to the ICPNQ, patients with grade 2 neuropathy with neuropathic pain and grade 3 neuropathy reported significantly worse scores on all EORTC QLQ-CIPN20 subscales compared with patients with lower CTC grades of peripheral neuropathy (P≤.002).
These patients also reported clinically relevant and statistically significant worse health-related quality of life score on nearly all EORTC-QLQ-C30 subscales.
Beijers AJM, Vreugdenhil G, Oerlemans S, et al. Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice [published online ahead of print December 3, 2015]. Supp Care Cancer. doi:10.1007/s00520-015-3032-y.